Telangana and China Medical City sign a MoU
February 06, 2015: The Telangana State Industrial Infrastructure Corporation recently signed a Memorandum of Understanding with China Medical City (CMC), by means of which the two will work together in the fields of life sciences, biotechnology and the development of medical devices.
CMC located in Taizhou, China, has become a hub for the development, syntheses and distribution of pharmaceutical and medical products. Of late, CMC has started focusing attention on the commercialization of finished products for developing nations.
This MoU was signed between the two parties at the BioAsia 2015 conference in January, which is an annual event hosted to provide a platform to display breakthroughs in the world of pharmaceuticals and health sciences.
The intent of this MoU is to provide networking channels which will help India collaborate with China and the rest of the world, in order to provide partnering options with pharmaceutical and biomedical organizations. TSIIC and CMU will function as a single entity, which will hold details on technology, research facilities and other relevant information, akin to a knowledge bank, and share this for a fee, to entities that may be interested in obtaining non-confidential data.
The MoU was signed in the presence of the Managing Director and Vice president of TSIIC, Mr. Jayesh Ranjan, and CMC’s Deputy Director, Mr. Liu Lu.
Apart from this major venture, CMC is working on setting up a cluster of life science centers in China. This has been funded and supported by Government of Jiangsu Province, The Ministry of Science and Technology, and the Board of Traditional Chinese Medicine.
CMC’s massive set up in Taizhou offers visitors and scientists an opportunity to tour their premises, explore their facilities, and access certain production and manufacturing areas, in order to better understand the pharmaceutical development processes. Workshops on foreign policies, investment procedures and economic development help organizations make informed decisions on potential collaborations.
Dr. Jay Shinde